Aytu BioScience Announces Leadership Change and Financial Growth

Aytu BioScience ( (AYTU) ) has provided an update.

Aytu BioPharma has announced significant organizational changes, including the termination of CFO Mark K. Oki and the appointment of Ryan Selhorn as the new CFO. The company reported a net income of $1.5 million in its fiscal 2025 first quarter, marking a financial turnaround led by increased revenues from its ADHD and pediatric portfolios. Aytu’s optimization efforts are expected to streamline operations and reduce expenses by $2 million annually, aiming to further boost profitability and enhance shareholder value.

Learn more about AYTU stock on TipRanks’ Stock Analysis page.